T-cells and TCRs reactive to cancer-specific antigens, including Dark Antigens or MR1-presented ligands, are being developed for TCR-directed T-cell therapy with future potential applicability for use with other modalities, such as bi-specific biologics.
Generating products for the broadest patient benefit
Our proprietary discovery platforms allow us to enable a diverse range of product candidates that can be advanced into to clinical development internally or through partnerships. Our primary focus is to develop TCR-directed T-cell therapies against shared targets with high prevalence and tumor homogeneity to ensure wide coverage across a given patient population.
Multiple Dark Antigens™ can be combined to create off-the-shelf therapeutic cancer vaccines or used to generate polyclonal autologous ex vivo stimulation T-cell products.